Scientists in Germany have made significant progress in developing a nasal vaccine that can effectively combat COVID-19. The vaccine, which uses a live but weakened form of the coronavirus, has been shown to achieve "sterilizing immunity" in hamsters, meaning it can prevent the virus from replicating in the animals' upper airways.
The vaccine works by boosting mucosal immunity, or immune defenses in the tissues that line the upper airways, where the virus typically enters the body. This approach is different from traditional vaccines, which work by triggering an immune response throughout the body.
In experiments with hamsters, two doses of the nasal vaccine were found to be more effective than other types of COVID-19 vaccines, including mRNA-based vaccines and those that use adenoviruses to deliver the vaccine instructions into cells. The researchers believe that the live weakened vaccine worked better because it closely mimics the process of a natural infection.
The vaccine also previews the entire coronavirus for the body, not just its spike proteins, which allows the hamsters to make immune weapons against a wider range of targets.
While the results are promising, experts caution that more tests need to be conducted before the vaccine can be widely used. The vaccine still has to pass clinical trials in humans and address potential challenges such as the virus mutating into new forms.
At least four nasal vaccines for COVID-19 have reached late-stage testing in people, according to the World Health Organization's vaccine tracker. However, other nasal vaccines are struggling to overcome technical hurdles, including respiratory infections proving to be tough targets for inhaled vaccines.
Overall, the development of a nasal vaccine that can effectively combat COVID-19 is an exciting area of research with potential benefits for global health.
The vaccine works by boosting mucosal immunity, or immune defenses in the tissues that line the upper airways, where the virus typically enters the body. This approach is different from traditional vaccines, which work by triggering an immune response throughout the body.
In experiments with hamsters, two doses of the nasal vaccine were found to be more effective than other types of COVID-19 vaccines, including mRNA-based vaccines and those that use adenoviruses to deliver the vaccine instructions into cells. The researchers believe that the live weakened vaccine worked better because it closely mimics the process of a natural infection.
The vaccine also previews the entire coronavirus for the body, not just its spike proteins, which allows the hamsters to make immune weapons against a wider range of targets.
While the results are promising, experts caution that more tests need to be conducted before the vaccine can be widely used. The vaccine still has to pass clinical trials in humans and address potential challenges such as the virus mutating into new forms.
At least four nasal vaccines for COVID-19 have reached late-stage testing in people, according to the World Health Organization's vaccine tracker. However, other nasal vaccines are struggling to overcome technical hurdles, including respiratory infections proving to be tough targets for inhaled vaccines.
Overall, the development of a nasal vaccine that can effectively combat COVID-19 is an exciting area of research with potential benefits for global health.